← All trials
NCT03582293
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 19, 2018
- Primary completion
- Sep 20, 2021
- Completion date
- Dec 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of AmsterdamLead sponsor
- Hersenstichting NederlandCollaborator
- University of AmsterdamReponsible party - principal investigator
- ZonMw: The Netherlands Organisation for Health Research and DevelopmentCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.